In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
about
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreMadurella mycetomatis is highly susceptible to ravuconazoleIn vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.Investigational antifungal agents.Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans.New and emerging antifungal agents: impact on respiratory infections.Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida sppIn vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.New and investigational triazole agents for the treatment of invasive fungal infections.In vitro antifungal susceptibility of Cryptococcus gattii.New generation azole antifungals in clinical investigation.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.In vitro studies of the activity of dithiocarbamate organoruthenium complexes against clinically relevant fungal pathogens.Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.Newer antifungal agents.Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China.Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study
P2860
Q24569706-ADF0A986-784A-4200-81E9-B2CB6CD2E9BFQ28539848-A2AE589A-D797-42CF-B1B9-53887EB9F898Q33696932-9675BC5E-4AF8-43D7-8C06-0CAF0EBCC3E5Q33859215-27052AA2-C211-47AB-9DF3-004050DCE1F8Q34113955-86CFEDE5-647D-4E47-B9BC-5492C5D0132DQ34335243-FEE865C4-95C4-4B61-B2FD-AB4E48590F5BQ34747071-146EA07B-DF41-411C-B956-756C37550586Q35627629-DEC7549A-BC56-4A51-B635-CBC891245753Q35714264-67BCDAE9-C253-4664-95EC-FF7C45F4D632Q36669593-A92F49CF-0EB3-4818-8DBC-B2A4DAC2D322Q37119029-A861E815-7B0A-4B04-9B39-F3EEA561246DQ37247728-78D6B2BB-7130-4430-9F28-010D09B80D94Q37364295-5D63333D-5DE8-4FED-ABBF-A68D457147B6Q37575561-2888438C-A245-44E2-A3AE-43340E633471Q37579222-DEC9D1C8-B25D-454A-8D81-4D73D80A3B3BQ37608276-1AAB30A5-0488-4DEA-B764-62F5E3CDA708Q38285488-6B2031C0-9D82-4C4F-A8EE-CF2ACF240C39Q38989873-220320EB-3E23-46FA-A5B1-E447705F31E6Q39732812-0FEA5261-5846-4203-B660-3F6F802ECD55Q40668115-764DEA34-8653-4764-B678-EC510AA77933Q42678650-39A8F0B9-996B-45E9-9211-CFE22ED7E0E6Q44855715-77CE25A8-BA21-4801-A821-8C5603AEA381Q45017876-89AAC5C8-373B-4D1E-9243-135519B7FAB4Q46711208-2AF788DA-4E19-4178-BA39-85E0C4590F38Q58697730-B416405E-973B-4EA4-8DBC-FD415E9C64F4
P2860
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
In vitro activities of ravucon ...... tes of Cryptococcus neoformans
@en
In vitro activities of ravuconazole
@nl
type
label
In vitro activities of ravucon ...... tes of Cryptococcus neoformans
@en
In vitro activities of ravuconazole
@nl
prefLabel
In vitro activities of ravucon ...... tes of Cryptococcus neoformans
@en
In vitro activities of ravuconazole
@nl
P2093
P2860
P1476
In vitro activities of ravucon ...... tes of Cryptococcus neoformans
@en
P2093
P2860
P304
P356
10.1128/AAC.44.10.2883-2886.2000
P407
P577
2000-10-01T00:00:00Z